|Stem Cell Summit 2017|
Stem Cell Research & Regenerative Medicine 2017
Stem Cell Product Development & Commercialization 2017
GTCbio is proud to present the Stem Cell Summit 2017, to be held on April 5-7, 2017 in Boston, MA. The Stem Cell Summit provides information on cutting-edge developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells. This summit comprises of presentations, panels and round-table discussions to highlight pre-clinical and clinical studies in regenerative medicine, immunotherapy, stem cell reprogramming, cell therapy in diabetes, regulatory policies regarding stem cell research, manufacturing and other relevant topics.
Stem Cell Summit 2017 includes two back-to-back conferences including joint plenary session:
Conference 1: 14th Stem Cell Research & Regenerative Medicine
- Advances in Adult & Pluripotent Stem Cell Research
- Revolution in Immunotherapy
- What’s in the Pipeline: Pre-clinical & Clinical Strategies
Joint: Plenary Session
- Where do We Stand with Cell Therapy in Diabetes?
Conference 2: 6th Stem Cell Product Development & Commercialization
- Regulatory Challenges in Cell Therapy
- Funding and Partnering
- Stem Cells for Drug Discovery & Disease Modeling
- Manufacturing and Scalable Processes
- Biotech Showcase: Emerging Pipelines
- Commercialization: Creating Sustainable Business Models
The 2017 Advisory Committee
|2017 Advisory Board Members|
|Stephen Chang, The New York Stem Cell Foundation|
|Douglas Losordo, Caladrius Biosciences|
|Robert Deans, BlueRock Therapeutics|
|Alain Vertes, NxR Biotechnologies GmbH|
|Daniel Anderson, Massachusetts Institute of Technology|
|Edward Lanphier, Sangamo Biosciences|
|Khalid Shah, Harvard Medical School; Massachusetts General Hospital|
|Yang (Ted) Teng, Harvard University and Spaulding Rehabilitation Hospital|
|James Ankrum, University of Iowa|
|Hardy T S Kagimoto, Healios K.K (RIKEN Venture)|
|Anthony Ting, Athersys|
|Robert Halliwell, University of the Pacific|
|Devyn Smith, Pfizer|
|Jiwen Zhang, GE Healthcare|
|Julie G. Allickson, Wake Forest Institute for Regenerative Medicine|
|Tiina Palomaki, Finnish Medicines Agency|
|Satish Medicetty, GTCbio|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Cancer Genetics Inc. (CGI; Nasdaq: CGIX) is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State. CGI has established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
BioSpherix will be exhibiting the Xvivo System, world’s first and only cytocentric barrier isolator optimized for cells. Economical and practical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Get better contamination, process and quality control. Stop by the BioSpherix booth to learn more about the only total quality platform for cells!
Diagenode, the leading provider of complete solutions for epigenetics research, offers innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. Our latest innovations include a full automation system, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies.
Absorption Systems assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) barriers in the development of drugs and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes whey they occur.
Biological Industries USA, Inc. (BI-USA) provides researchers direct access to an entire portfolio of GMP-defined, optimized solutions for stem cell research and scale-up including NutriStem® – a serum-free; xeno-free media for the growth and expansion of pluripotent stem cells and mesenchymal stem cells, CryoStem™ Freezing Medium, MSC differentiation kits, and PLTMax® human platelet lysate.
CBSET is a nonprofit biomedical research institute with a mission is to advance therapeutics development through high-quality services. We collaborate with med tech and pharmaceutical sponsors with a GLP-compliant, AAALAC-accredited facility including vivaria, catheterization / imaging labs, surgical and necropsy suites, histopathology, SEM, and a range of other technologies.